Browse Studies — Arctuva

Phase 3

A Phase 3 Study to Investigate the Safety, Tolerability, and Immunogenicity of Revaccinating Pregnant Participants During Subsequent Pregnancies and Persistence of Immunity of a Single Dose of a Bivalent Respiratory Syncytial Virus (RSV) Vaccine.

This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts fr…

RSV Infection

Estimated

~$10 – $7,500

PfizerNCT06866405

Phase 4

Longitudinal Serum and Mucosal RSV Antibodies Following Clesrovimab (Enflonsia™, Merck) Administration in Infants During Their First Respiratory Season or [The EMBRACE Study: Enflonsia™ Monoclonal in Babies - RSV Antibody Concentration Evaluation]

Clesrovimab is an FDA-approved antibody drug recommended for infants younger than 8 months who are entering their first respiratory syncytial virus (RSV) seaso…

RSV Infection

Estimated

~$10 – $6,250

Emory UniversityNCT07824167

Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

The purpose of this study is to continue evaluating how well the RSV vaccines work as they are currently being used in routine clinical practice. Some of the q…

RSV Infection

Estimated

~$10 – $750

Yale UniversityNCT06172660

Phase 1

A Phase 1, Placebo-controlled, Randomized, Observer-blind Study to Describe the Safety, Tolerability and Immunogenicity of SCB-1019T in Adults Who Were Vaccinated With AREXVY at Least 18 Months Before

CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability…

RSV Infection

Estimated

~$10 – $8,750

Clover Biopharmaceuticals USA, LLCNCT06843317